What is value investing and how do I pick stocks which might rise in share price? Patience and a good eye for judging a company’s future prospects are important - but beware the ‘value trap’ The Independent UK · Jun 25
MarketBeat Week in Review – 06/08 - 06/12 Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum MarketBeat · Jun 13
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. MarketBeat · Jun 11
FDA issues new kidney warning for weight loss pill Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration The Independent UK · Jun 11
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock? Barchart · Jun 9
More swings for AI stocks drag Wall Street back on the roller coaster More sudden reversals for high-flying artificial-intelligence stocks sent Wall Street reeling AAP · Jun 9
Another sell-off for AI stocks sends Wall Street reeling Another sell-off for artificial-intelligence stocks whipsawed Wall Street AAP · Jun 9
Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapse The US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion in market value within just two hours. What began as a relief rally suddenly turned into a broad sell-off that dragged down the Nasdaq, Nvidia, Apple,… The Economic Times · Jun 9
Another sell-off for AI stocks drags Wall Street sharply lower Another sell-off for artificial-intelligence stocks is dragging Wall Street sharply lower AAP · Jun 9
Wall Street falls sharply as AI stocks resume their sell-off Artificial-intelligence stocks are resuming their sell-off, and the former superstars that had led the market to records are dragging Wall Street down with them AAP · Jun 9
FTSE 100 down as Asia-focused financials struggle Oil prices also fell after US President Donald Trump said negotiations over a peace deal to end the Middle East war were in their final stages. Evening Standard · Jun 9
Wall Street drops as AI stocks slide sharply again Artificial-intelligence stocks are tumbling again, and the former superstars that had led the market to records are dragging Wall Street along with them AAP · Jun 9
Wall Street yo-yos as AI stocks swing from gains to losses The U.S. stock market is yo-yoing as artificial-intelligence stocks keep swinging following their sudden and sharp losses from last week AAP · Jun 9
Wall Street ticks higher as AI stocks recover more losses and oil prices ease The U.S. stock market is ticking higher as artificial-intelligence stocks regain more of their sudden and sharp losses from last week, while oil prices ease AAP · Jun 9
The Economic Times · Jun 9 Global Markets: European shares edge higher with banks in the lead; the Middle East in focus European markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after recent volatility. GSK shares fell following a deal to acquire Nuvalent. UBS saw an increase on reports of potential capital requirement adjustments. Investors monitored developments in the Middle East…
The Guardian - UK · Jun 9 GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year
Evening Standard · Jun 9 GSK to buy US lung cancer drug specialist Nuvalent for £8bn The acquisition is thought to be GSK’s biggest deal in more than a decade.
AAP · May 28 Experimental hepatitis B drug may offer 'functional cure' for some patients New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
The Economic Times · May 28 GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with…
AAP · May 28 Experimental hepatitis B drug might offer 'functional cure' for a subset of patients New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
The Independent UK · May 28 FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
The Conversation · May 19 Wise leadership pays off. Here’s how to apply it in the workplace In a global context marked by chaos and turbulence, technological advancements, health crises, marketplace alterations, shifting demographics and organizational foolishness, the demand for more adaptive and reflective forms of leadership has become a necessity. Given this context, wisdom can provide a meaningful understanding of “good” leadership to navigate such turbulence…
Barchart · May 14 Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death. The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.
MarketBeat · May 2 The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.